These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37769168)

  • 41. Genetic testing for familial hypercholesterolemia: Impact on diagnosis, treatment and cardiovascular risk.
    Lee S; Akioyamen LE; Aljenedil S; Rivière JB; Ruel I; Genest J
    Eur J Prev Cardiol; 2019 Aug; 26(12):1262-1270. PubMed ID: 30755017
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Familial hypercholesterolemia and cardiovascular disease in older individuals.
    Coutinho ER; Miname MH; Rocha VZ; Bittencourt MS; Jannes CE; Tada MT; Lima IR; Filho WS; Chacra AP; Pereira AC; Krieger JE; Santos RD
    Atherosclerosis; 2021 Feb; 318():32-37. PubMed ID: 33450476
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH).
    Rizos CV; Elisaf MS; Skoumas I; Tziomalos K; Kotsis V; Rallidis L; Garoufi A; Athyros VG; Skalidis E; Kolovou G; Koutagiar I; Papagianni M; Antza C; Katsiki N; Ganotakis E; Liberopoulos EN
    Atherosclerosis; 2018 Oct; 277():308-313. PubMed ID: 30270064
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis.
    Leipold R; Raal F; Ishak J; Hovingh K; Phillips H
    Eur J Prev Cardiol; 2017 Nov; 24(17):1843-1850. PubMed ID: 28925748
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of cardiovascular risk factors in patients with familial hypercholesterolemia from the North-Eastern area of Romania.
    Vlad CE; Foia L; Florea L; Costache II; Covic A; Popescu R; Reurean-Pintilei D; Covic A
    Lipids Health Dis; 2021 Jan; 20(1):4. PubMed ID: 33430859
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.
    Bell DA; Hooper AJ; Watts GF; Burnett JR
    Vasc Health Risk Manag; 2012; 8():651-9. PubMed ID: 23226021
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
    Robinson JG
    J Manag Care Pharm; 2013 Mar; 19(2):139-49. PubMed ID: 23461430
    [TBL] [Abstract][Full Text] [Related]  

  • 48. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
    Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M
    Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
    Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
    J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A familial hypercholesterolemia registry as the main tool for adequate management of the disease.
    Korneva VA; Kuznetsova TY; Julius U
    Ther Apher Dial; 2022 Dec; 26 Suppl 1():73-80. PubMed ID: 36468285
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Familial hypercholesterolemia: experience from the French-Canadian population.
    Paquette M; Genest J; Baass A
    Curr Opin Lipidol; 2018 Apr; 29(2):59-64. PubMed ID: 29356704
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sex Differences in Familial Hypercholesterolemia.
    Klevmoen M; Mulder JWCM; Roeters van Lennep JE; Holven KB
    Curr Atheroscler Rep; 2023 Nov; 25(11):861-868. PubMed ID: 37815650
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Universal screening for familial hypercholesterolemia in children: The Slovenian model and literature review.
    Groselj U; Kovac J; Sustar U; Mlinaric M; Fras Z; Podkrajsek KT; Battelino T
    Atherosclerosis; 2018 Oct; 277():383-391. PubMed ID: 30270075
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Familial Hypercholesterolemia and Lipoprotein(a): Two Partners in Crime?
    Alonso R; Argüeso R; Álvarez-Baños P; Muñiz-Grijalvo O; Diaz-Diaz JL; Mata P
    Curr Atheroscler Rep; 2022 Jun; 24(6):427-434. PubMed ID: 35386090
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cardiovascular disease onset in old people with severe hypercholesterolemia.
    Coutinho ER; Miname MH; Rocha VZ; Bittencourt MS; Jannes CE; Krieger JE; Pereira AC; Santos RD
    Atherosclerosis; 2023 Jan; 365():9-14. PubMed ID: 36646017
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers.
    Besseling J; Kindt I; Hof M; Kastelein JJ; Hutten BA; Hovingh GK
    Atherosclerosis; 2014 Mar; 233(1):219-23. PubMed ID: 24529147
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Barriers and shortcomings in access to cardiovascular management and prevention for familial hypercholesterolemia during the COVID-19 pandemic.
    Huang H; Leung KSK; Garg T; Mazzoleni A; Miteu GD; Zakariya F; Awuah WA; Yin ETS; Haroon F; Hussain Z; Aji N; Jaiswal V; Tse G
    Clin Cardiol; 2023 Aug; 46(8):831-844. PubMed ID: 37260143
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).
    EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
    Lancet; 2021 Nov; 398(10312):1713-1725. PubMed ID: 34506743
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel therapies for treating familial hypercholesterolemia.
    Bandeali SJ; Daye J; Virani SS
    Curr Atheroscler Rep; 2014 Jan; 16(1):382. PubMed ID: 24293346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.